XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating activities:    
Net income (loss) $ 99,304 $ (87,747)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation 9,345 7,650
Amortization of right-of-use operating lease assets 1,433 0
Amortization of patents 1,139 1,356
Amortization of premium (discount) on investments, net (7,064) 791
Amortization of debt issuance costs 1,448 1,343
Amortization of convertible senior notes discount 26,747 24,781
Stock-based compensation expense 111,564 97,210
Non-cash losses related to patents, licensing and property, plant and equipment 216 482
Provision for deferred income taxes 4,103 0
Changes in operating assets and liabilities:    
Contracts receivable (33,716) 48,223
Inventories (6,606) 1,604
Other current and long-term assets (23,377) (26,573)
Accounts payable (18,764) (13,606)
Accrued compensation (4,864) (892)
Accrued liabilities and deferred rent 3,909 (14,392)
Deferred contract revenue (97,029) 447,168
Net cash provided by operating activities 67,788 487,398
Investing activities:    
Purchases of short-term investments (1,617,726) (1,156,335)
Proceeds from short-term investments 1,465,600 568,517
Purchases of property, plant and equipment (23,143) (12,221)
Acquisition of licenses and other assets, net (4,196) (3,317)
Net cash used in investing activities (179,465) (603,356)
Financing activities:    
Proceeds from equity awards 112,137 18,254
Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options (18,841) 0
Proceeds from the issuance of common stock to Biogen 0 447,965
Principal payments on debt obligations (12,500) 0
Net cash provided by financing activities 80,796 466,219
Net increase in cash and cash equivalents (30,881) 350,261
Cash and cash equivalents at beginning of period 278,820 129,630
Cash and cash equivalents at end of period 247,939 479,891
Supplemental disclosures of cash flow information:    
Interest paid 5,474 5,434
Income taxes paid 9,037 0
Supplemental disclosures of non-cash investing and financing activities:    
Right-of-use assets obtained in exchange for lease obligations 14,178 0
Amounts accrued for capital and patent expenditures 3,251 2,296
Purchases of property, plant and equipment included in long-term obligations $ 0 $ 3,596